🚀 VC round data is live in beta, check it out!
Egetis Therapeutics Valuation Multiples
Discover revenue and EBITDA valuation multiples for Egetis Therapeutics and similar public comparables like MediWound, Acepodia, Pyridam Farma, Keros Therapeutics and more.
Egetis Therapeutics Overview
About Egetis Therapeutics
Egetis Therapeutics AB is an integrated pharmaceutical drug development company, focusing on projects in late-stage development for the treatment of serious rare/niche diseases with unmet medical needs in the orphan drug segment.
Founded
2007
HQ
Employees
11
Website
Sectors
Financials (LTM)
EV
$214M
Egetis Therapeutics Financials
Egetis Therapeutics reported last 12-month revenue of $21M and negative EBITDA of ($17M).
In the same LTM period, Egetis Therapeutics generated $18M in gross profit, ($17M) in EBITDA losses, and had net loss of ($18M).
Revenue (LTM)
Egetis Therapeutics P&L
In the most recent fiscal year, Egetis Therapeutics reported revenue of $8M and EBITDA of ($32M).
Egetis Therapeutics expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $21M | XXX | $8M | XXX | XXX | XXX |
| Gross Profit | $18M | XXX | $1M | XXX | XXX | XXX |
| Gross Margin | 85% | XXX | 18% | XXX | XXX | XXX |
| EBITDA | ($17M) | XXX | ($32M) | XXX | XXX | XXX |
| EBITDA Margin | (79%) | XXX | (413%) | XXX | XXX | XXX |
| EBIT Margin | (83%) | XXX | (469%) | XXX | XXX | XXX |
| Net Profit | ($18M) | XXX | ($35M) | XXX | XXX | XXX |
| Net Margin | (84%) | XXX | (461%) | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Egetis Therapeutics Stock Performance
Egetis Therapeutics has current market cap of $228M, and enterprise value of $214M.
Market Cap Evolution
Egetis Therapeutics' stock price is $0.58.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $214M | $228M | -7.1% | XXX | XXX | XXX | $-0.09 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialEgetis Therapeutics Valuation Multiples
Egetis Therapeutics trades at 10.1x EV/Revenue multiple, and (12.9x) EV/EBITDA.
EV / Revenue (LTM)
Egetis Therapeutics Financial Valuation Multiples
As of April 18, 2026, Egetis Therapeutics has market cap of $228M and EV of $214M.
Equity research analysts estimate Egetis Therapeutics' 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Egetis Therapeutics has a P/E ratio of (12.8x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $228M | XXX | $228M | XXX | XXX | XXX |
| EV (current) | $214M | XXX | $214M | XXX | XXX | XXX |
| EV/Revenue | 10.1x | XXX | 28.0x | XXX | XXX | XXX |
| EV/EBITDA | (12.9x) | XXX | (6.8x) | XXX | XXX | XXX |
| EV/EBIT | (12.1x) | XXX | (6.0x) | XXX | XXX | XXX |
| EV/Gross Profit | 11.8x | XXX | 158.8x | XXX | XXX | XXX |
| P/E | (12.8x) | XXX | (6.5x) | XXX | XXX | XXX |
| EV/FCF | (10.6x) | XXX | (7.3x) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Egetis Therapeutics Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Egetis Therapeutics Margins & Growth Rates
Egetis Therapeutics' revenue in the last 12 month grew by 165%.
Egetis Therapeutics' revenue per employee in the last FY averaged $0.7M, while opex per employee averaged $3.4M for the same period.
Egetis Therapeutics' rule of 40 is 736% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Egetis Therapeutics' rule of X is 1768% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Egetis Therapeutics Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 165% | XXX | 599% | XXX | XXX | XXX |
| EBITDA Margin | (79%) | XXX | (413%) | XXX | XXX | XXX |
| EBITDA Growth | (235%) | XXX | (182%) | XXX | XXX | XXX |
| Rule of 40 | — | XXX | 736% | XXX | XXX | XXX |
| Bessemer Rule of X | — | XXX | 1768% | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.7M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $3.4M | XXX | XXX | XXX |
| S&M Expenses to Revenue | — | XXX | 138% | XXX | XXX | XXX |
| G&A Expenses to Revenue | — | XXX | 147% | XXX | XXX | XXX |
| R&D Expenses to Revenue | — | XXX | 225% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 487% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Egetis Therapeutics Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Egetis Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| MediWound | XXX | XXX | XXX | XXX | XXX | XXX |
| Acepodia | XXX | XXX | XXX | XXX | XXX | XXX |
| Pyridam Farma | XXX | XXX | XXX | XXX | XXX | XXX |
| Keros Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Context Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Egetis Therapeutics M&A Activity
Egetis Therapeutics acquired XXX companies to date.
Last acquisition by Egetis Therapeutics was on XXXXXXXX, XXXXX. Egetis Therapeutics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Egetis Therapeutics
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialEgetis Therapeutics Investment Activity
Egetis Therapeutics invested in XXX companies to date.
Egetis Therapeutics made its latest investment on XXXXXXXX, XXXXX. Egetis Therapeutics invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Egetis Therapeutics
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Egetis Therapeutics
| When was Egetis Therapeutics founded? | Egetis Therapeutics was founded in 2007. |
| Where is Egetis Therapeutics headquartered? | Egetis Therapeutics is headquartered in Sweden. |
| How many employees does Egetis Therapeutics have? | As of today, Egetis Therapeutics has over 11 employees. |
| Who is the CEO of Egetis Therapeutics? | Egetis Therapeutics' CEO is Nicklas Westerholm. |
| Is Egetis Therapeutics publicly listed? | Yes, Egetis Therapeutics is a public company listed on Nasdaq Stockholm. |
| What is the stock symbol of Egetis Therapeutics? | Egetis Therapeutics trades under EGTX ticker. |
| When did Egetis Therapeutics go public? | Egetis Therapeutics went public in 2011. |
| Who are competitors of Egetis Therapeutics? | Egetis Therapeutics main competitors are MediWound, Acepodia, Pyridam Farma, Keros Therapeutics. |
| What is the current market cap of Egetis Therapeutics? | Egetis Therapeutics' current market cap is $228M. |
| What is the current revenue of Egetis Therapeutics? | Egetis Therapeutics' last 12 months revenue is $21M. |
| What is the current revenue growth of Egetis Therapeutics? | Egetis Therapeutics revenue growth (NTM/LTM) is 165%. |
| What is the current EV/Revenue multiple of Egetis Therapeutics? | Current revenue multiple of Egetis Therapeutics is 10.1x. |
| Is Egetis Therapeutics profitable? | No, Egetis Therapeutics is not profitable. |
| What is the current EBITDA of Egetis Therapeutics? | Egetis Therapeutics has negative EBITDA and is not profitable. |
| What is Egetis Therapeutics' EBITDA margin? | Egetis Therapeutics' last 12 months EBITDA margin is (79%). |
| What is the current EV/EBITDA multiple of Egetis Therapeutics? | Current EBITDA multiple of Egetis Therapeutics is (12.9x). |
| What is the current FCF of Egetis Therapeutics? | Egetis Therapeutics' last 12 months FCF is ($20M). |
| What is Egetis Therapeutics' FCF margin? | Egetis Therapeutics' last 12 months FCF margin is (96%). |
| What is the current EV/FCF multiple of Egetis Therapeutics? | Current FCF multiple of Egetis Therapeutics is (10.6x). |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.